These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 10746974)

  • 1. Cisplatin containing chemotherapy influences HLA-DR expression on monocytes from cancer patients.
    Novellino PS; Trejo YG; Beviacqua M; Bordenave RH; Rumi LS
    J Exp Clin Cancer Res; 1999 Dec; 18(4):481-4. PubMed ID: 10746974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor-alfa production by monocytes from lung and colorectal cancer patients.
    Trejo YG; Bordenave RH; Beviacqua M; Zanoni L; Rumi LS
    J Exp Clin Cancer Res; 2001 Mar; 20(1):71-3. PubMed ID: 11370833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent.
    Pujol JL; Carestia L; Daurès JP
    Br J Cancer; 2000 Jul; 83(1):8-15. PubMed ID: 10883661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
    J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of interleukin-10 mRNA expression in peripheral leukocytes predicts poor outcome and diminished human leukocyte antigen-DR expression on monocytes in septic patients.
    Abe R; Hirasawa H; Oda S; Sadahiro T; Nakamura M; Watanabe E; Nakada TA; Hatano M; Tokuhisa T
    J Surg Res; 2008 Jun; 147(1):1-8. PubMed ID: 17720196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: a Phase III study.
    Dimitroulis J; Rapti A; Stathopoulos GP; Rigatos S; Stathopoulos J; Koutantos J; Athanasiadis A; Tsikritsaki K; Karaindros D; Katis K; Antoniou D; Toumbis M; Giamboudakis P
    Oncol Rep; 2008 Oct; 20(4):879-84. PubMed ID: 18813830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relationship between surface HLA-DR expression and NBT reduction in monocytes in patients with colorectal cancer].
    Novellino PS; Trejo YG; Fernández O; Bordenave H; Rumi LS
    Sangre (Barc); 1991 Apr; 36(2):99-103. PubMed ID: 1866661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Paclitaxel and cisplatin combined with etoposide chemotherapy in non-small cell lung cancer with brain metastases].
    Yang QY; Chen LK; Xu GC; Liu JL; Liang Y; Zhang LN
    Ai Zheng; 2004 Nov; 23(11 Suppl):1459-62. PubMed ID: 15566657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human leukocyte antigen-DR expression on peripheral blood monocytes and the risk of pneumonia in pediatric lung transplant recipients.
    Hoffman JA; Weinberg KI; Azen CG; Horn MV; Dukes L; Starnes VA; Woo MS
    Transpl Infect Dis; 2004 Dec; 6(4):147-55. PubMed ID: 15762932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
    Kakolyris S; Agelidou A; Androulakis N; Tsaroucha E; Kouroussis Ch; Agelidou M; Karvounis N; Veslemes M; Christophylakis Ch; Argyraki A; Geroyianni A; Georgoulias V
    Lung Cancer; 2006 Jul; 53(1):59-65. PubMed ID: 16716447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis.
    Yüksel M; Cermik TF; Doğanay L; Karlikaya C; Cakir E; Salan A; Berkarda S
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):876-81. PubMed ID: 12111127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101).
    Tsuchiya R; Suzuki K; Ichinose Y; Watanabe Y; Yasumitsu T; Ishizuka N; Kato H
    J Thorac Cardiovasc Surg; 2005 May; 129(5):977-83. PubMed ID: 15867769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer.
    Schmidinger M; Budinsky AC; Wenzel C; Piribauer M; Brix R; Kautzky M; Oder W; Locker GJ; Zielinski CC; Steger GG
    Wien Klin Wochenschr; 2000 Jul; 112(14):617-23. PubMed ID: 11008323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemotherapy in extended small-cell lung cancer. Retrospective analysis of two different series of patients treated with carboplatin and etoposide or ciclophosphamide-epidoxorubicin and etoposide].
    Tassinari D; Genestreti G; Pasquini E; Fantini M; Poggi B; Tamburini E; Papi M; Ioli G; Oliverio G; Fochessati F; Arcangeli V; Agostini V; Mianulli AM; Imola M; Fattori PP; Ravaioli A
    Recenti Prog Med; 2005 May; 96(5):234-9. PubMed ID: 15977652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of combination chemotherapy to adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in patients with gastric or colorectal cancer].
    Kamoshita N; Yokomori T; Iesato H; Ohya T; Nagaoka H; Okabe T; Kato Y; Takeyoshi I; Ohwada S; Morishita Y
    Gan To Kagaku Ryoho; 2000 May; 27(5):711-6. PubMed ID: 10832439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
    Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
    Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
    Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
    Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer.
    Schild SE; Bonner JA; Shanahan TG; Brooks BJ; Marks RS; Geyer SM; Hillman SL; Farr GH; Tazelaar HD; Krook JE; Geoffroy FJ; Salim M; Arusell RM; Mailliard JA; Schaefer PL; Jett JR
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):943-51. PubMed ID: 15234027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.